Home › Biliary Tract Cancer › Illinois
Biliary Tract Cancer clinical trials in Illinois
6 studies for Biliary Tract Cancer are looking for participants at sites in Illinois.
Cities in Illinois
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Chicago
- Research Site, Niles
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Oct 13, 2026 · NCT06467357Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- City of Hope - Chicago Cancer Center (Site 128), Zion
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Chicago
- Research Site, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07221253From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.